Hoffmann, V. S., & Hehlmann, R. (2017). Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Journal of cancer research and clinical oncology, 143(7), . https://doi.org/10.1007/s00432-017-2385-7
Chicago-Zitierstil (17. Ausg.)Hoffmann, Verena Sophia, und Rüdiger Hehlmann. "Systematic Review and Meta-analysis of Standard-dose Imatinib Vs. High-dose Imatinib and Second Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia." Journal of Cancer Research and Clinical Oncology 143, no. 7 (2017). https://doi.org/10.1007/s00432-017-2385-7.
MLA-Zitierstil (9. Ausg.)Hoffmann, Verena Sophia, und Rüdiger Hehlmann. "Systematic Review and Meta-analysis of Standard-dose Imatinib Vs. High-dose Imatinib and Second Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia." Journal of Cancer Research and Clinical Oncology, vol. 143, no. 7, 2017, https://doi.org/10.1007/s00432-017-2385-7.